C4 Therapeutics
Manufacturing · Tennessee, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
490 Arsenal Way Ste 120, Watertown, Tenn...Phone Number
(617) 231-0700Website
www.c4therapeutics.comRevenue
$34.9 MillionStock Symbol
CCCCIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About C4 Therapeutics
C4 Therapeutics is a clinical-stage biotechnology company developing a new generation of medicines that harness targeted protein degradation (TPD) to transform how disease is treated. Our leadership team is comprised of experts in their fields, with experience spanning across leading biopharma organizations. Together, our team has experience in all the key disciplines needed to make new innovative technologies a reality for patients.Explore more
C4 Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is C4 Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if C4 Therapeutics had a recent Job posting/layoffs
Check if C4 Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when C4 Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on C4 Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once C4 Therapeutics has new funding data
Check out if C4 Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at C4 Therapeutics
C4 Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to C4 Therapeutics
Compare insights from companies similar to C4 Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
C4 Therapeutics
$34.9M
51-200
Public
$425M
2015
Kendra AdamsChief Financial Officer & Head Corporate Affairs & Principal Accounting Officer
Company Profile Activity
Activity Insights
C4 Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
C4 Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about C4 Therapeutics.
C4 Therapeutics financials insights
Gather financial insights about C4 Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$73M
2020
Multiple Rounds
$352M
C4 Therapeutics Tech Stack
A closer look at the technologies used by C4 Therapeutics
Most Recent Scoops
Project
C4 Therapeutics has reported efficacy data from the phase I trial of cemsidomide, with an overall response rate of 53% at the recommended phase dose of 100 micrograms (19 patients), including two stringent complete responses with MRD negativity, and an overall response rate of 36% across all dose levels in combination with dexamethasone.
Medical Research, Clinical Operations
Project
C4 Therapeutics has initiated enrollment in the phase II MOMENTUM trial of cemsidomide in the late-line multiple myeloma setting, with enrollment on track to complete by the end of Q1 2027 and initial overall response rate data expected in the second half of 2027, positioning the trial for potential accelerated approval.
Medical Research, Pharmaceuticals, Clinical Operations
Project
C4 Therapeutics has completed enrollment in the phase I first-in-human trial of cemsidomide as of September 2025, with updated data presented at EHA; the trial enrolled 73 patients across multiple dose levels, declared 100 micrograms as the recommended phase 2 dose (RP2D).
Pharmaceuticals, Clinical Operations
Project
C4 Therapeutics has guided to initial investigator-assessed data from the MOMENTUM study in the second half of 2027, with the regulatory independent monitoring committee endpoint and durability data expected in mid-2028.
Medical Research, Clinical Operations
Project
Medical Research, Clinical Operations
C4 Therapeutics News & Media
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide June 18, 2026 9:00 AM...C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative StatusC4 Therapeutics to Participate in Upcoming Conferences
WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in the upcoming conferences.C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company’s common stock to one new employee (the “Inducement Grant”),
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding C4 Therapeutics
Sign Up For FreeTo access detailed company insights
C4 Therapeutics is a clinical-stage biotechnology company developing a new generation of medicines that harness targeted protein degradation (TPD) to transform how disease is treated. Our leadership team is comprised of experts in their fields, with experience spanning across leading biopharma organizations. Together, our team has experience in all... Read More
